home
顺序
主题
题目
日子
76
HLB confirms Superior mPFS of Phase III Results of Rivoceranib on NSCLC
admin
2020.09.21
75
HLB opens the result of Phase III Results of Rivoceranib on Thyroid Cancer at ESMO
admin
2020.09.18
74
HLB draws a ‘Meaningful Result’ from Rivoceranib on Esophageal Cancer
admin
2020.09.17
73
HLB announces Rivoceranib Combo Phase II Results on Liver Cancer
admin
2020.09.15
72
ITI to Participate at World Vaccine Congress Washington 2020
admin
2020.09.15
71
HLB secures Global Rights of Rivoceranib and becomes a Royalty-receiving Company
admin
2020.09.07
70
Immunomic Therapeutics selected as a key player of COVID-19 vaccine development
admin
2020.08.18
69
HLB receives IND Approval for the Global Phase III of Primary Liver Cancer Treatment from KFDA
admin
2020.08.13
68
Elevar Therapeutics and Tanner Pharma Group announce Global Named Patient Program to provide access to Apealea®
admin
2020.07.28
67
Replicate Bioscience and ITI Form Collaboration to Combat Infectious Diseases and Cancers
admin
2020.06.25